Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
| Autor: | Maria Prendecki, Eleanor Parker, Graham Pickard, Louise Greathead, Megan Griffith, Richard S. Tedder, Myra O. McClure, Alison J. Cox, Claire Edwards, Paul Randell, Liz Lightstone, Virginia Prout, Michelle Willicombe, Stephen P. McAdoo, Amrita Dhutia, Rawya Charif, Federica Marchesin, Jaslyn Gan, Candice Clarke, Mary Guckian, Peter Kelleher |
|---|---|
| Přispěvatelé: | Imperial Health Charity |
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Cellular immunity medicine.medical_specialty T cell medicine.medical_treatment 030232 urology & nephrology serology Antibodies Viral Polymerase Chain Reaction Gastroenterology Asymptomatic Serology 03 medical and health sciences COVID-19 Testing 0302 clinical medicine Immune system Renal Dialysis Immunity Internal medicine Humans Medicine Serologic Tests Clinical Investigation Pandemics hemodialysis biology SARS-CoV-2 business.industry COVID-19 1103 Clinical Sciences Urology & Nephrology Haemodialysis 030104 developmental biology medicine.anatomical_structure Nephrology Reinfection biology.protein Kidney Failure Chronic Female Hemodialysis medicine.symptom Antibody business |
| Zdroj: | Kidney International |
| ISSN: | 0085-2538 |
| Popis: | Patients with end stage kidney disease receiving in-center hemodialysis (ICHD) have had high rates of SARS-CoV-2 infection. Following infection, patients receiving ICHD frequently develop circulating antibodies to SARS-CoV-2, even with asymptomatic infection. Here, we investigated the durability and functionality of the immune responses to SARS-CoV-2 infection in patients receiving ICHD. Three hundred and fifty-six such patients were longitudinally screened for SARS-CoV-2 antibodies and underwent routine PCR-testing for symptomatic and asymptomatic infection. Patients were regularly screened for nucleocapsid protein (anti-NP) and receptor binding domain (anti-RBD) antibodies, and those who became seronegative at six months were screened for SARS-CoV-2 specific T-cell responses. One hundred and twenty-nine (36.2%) patients had detectable antibody to anti-NP at time zero, of whom 127 also had detectable anti-RBD. Significantly, at six months, 71/111 (64.0%) and 99/116 (85.3%) remained anti-NP and anti-RBD seropositive, respectively. For patients who retained antibody, both anti-NP and anti-RBD levels were reduced significantly after six months. Eleven patients who were anti-NP seropositive at time zero, had no detectable antibody at six months; of whom eight were found to have SARS-CoV-2 antigen specific T cell responses. Independent of antibody status at six months, patients with baseline positive SARS-CoV-2 serology were significantly less likely to have PCR confirmed infection over the following six months. Thus, patients receiving ICHD mount durable immune responses six months post SARS-CoV-2 infection, with fewer than 3% of patients showing no evidence of humoral or cellular immunity. Graphical abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|